JNJ-6143 Elicits PSA Responses in Heavily Pretreated mCRPC
Johnson & Johnson's investigational therapy JNJ-6143 showed significant PSA declines and radiographic responses in heavily pretreated mCRPC patients, according to phase 1 study results. Among 38 patients, 77% had a confirmed PSA decline of at least 50%, and 48% had a decline of at least 90%. The confirmed objective response rate was 69% in patients with measurable disease. The study identified 50 mg once daily as the recommended phase 2 dose, and a phase 2 study has been initiated.
How this was made
The 30-second read
Why it matters
The data suggest a novel mechanism could address an unmet need in advanced prostate cancer, potentially adding a high‑value asset to J&J's portfolio.
Market read
Positive trial data may drive short‑term buying interest in JNJ and influence biotech sector sentiment.
What to watch
Potential safety signals in larger populations and competition from other AR‑targeted agents could temper upside.
Background
Johnson & Johnson presented phase 1 results for its oral RIPTAC candidate JNJ-6143 at ESMO 2026, highlighting deep PSA declines in heavily pre‑treated mCRPC patients.
Ticker impact
Phase 1 data shows 77% PSA50 response and 69% ORR at RP2D, a first public disclosure of JNJ-6143 efficacy.
potential upside as market prices in the strong response rates
First report of deep PSA declines and high objective response rate; fast‑track designation already known, but efficacy data are new and material.
Market effects
May boost broader biotech and prostate‑cancer therapeutic sector as a proof‑of‑concept for RIPTAC molecules.
U.S. biotech equities could see modest gains, especially peers developing AR‑targeted therapies.
Limited to investors tracking J&J and oncology pipelines; no immediate macro effect.
Counterpoint
Early‑stage data may not translate to later trials; investors could be cautious until Phase 2/3 results.
Key entities
- companyJohnson & Johnson
Developer of JNJ-6143, a first‑in‑class RIPTAC molecule.
- organizationEuropean Society for Medical Oncology (ESMO)
Venue where the trial data were presented.
